IRIS
SPAGNOLO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7.967
AS - Asia 1.549
NA - Nord America 1.529
Continente sconosciuto - Info sul continente non disponibili 295
SA - Sud America 127
AF - Africa 33
OC - Oceania 6
Totale 11.506
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 7.677
US - Stati Uniti d'America 1.433
SG - Singapore 506
CN - Cina 413
VN - Vietnam 263
BD - Bangladesh 177
BR - Brasile 76
FR - Francia 75
HK - Hong Kong 71
FI - Finlandia 63
DE - Germania 47
CA - Canada 46
JP - Giappone 27
AR - Argentina 18
GB - Regno Unito 15
IN - India 15
NL - Olanda 15
MX - Messico 14
ES - Italia 12
ID - Indonesia 12
JM - Giamaica 11
AT - Austria 9
CH - Svizzera 9
CO - Colombia 9
PL - Polonia 9
IQ - Iraq 8
TR - Turchia 7
ZA - Sudafrica 7
AU - Australia 6
EG - Egitto 6
IE - Irlanda 6
MY - Malesia 6
EC - Ecuador 5
PH - Filippine 5
PY - Paraguay 5
RU - Federazione Russa 5
UA - Ucraina 5
DO - Repubblica Dominicana 4
DZ - Algeria 4
GT - Guatemala 4
HN - Honduras 4
IL - Israele 4
KR - Corea 4
RO - Romania 4
SA - Arabia Saudita 4
UY - Uruguay 4
UZ - Uzbekistan 4
VE - Venezuela 4
AO - Angola 3
CL - Cile 3
LT - Lituania 3
MA - Marocco 3
NP - Nepal 3
PK - Pakistan 3
RS - Serbia 3
TN - Tunisia 3
AZ - Azerbaigian 2
CY - Cipro 2
HR - Croazia 2
KE - Kenya 2
KW - Kuwait 2
NI - Nicaragua 2
OM - Oman 2
PA - Panama 2
SE - Svezia 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AM - Armenia 1
BB - Barbados 1
BE - Belgio 1
BS - Bahamas 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
ET - Etiopia 1
GE - Georgia 1
GR - Grecia 1
GY - Guiana 1
KH - Cambogia 1
KZ - Kazakistan 1
LB - Libano 1
ME - Montenegro 1
MU - Mauritius 1
PE - Perù 1
PR - Porto Rico 1
PS - Palestinian Territory 1
QA - Qatar 1
SC - Seychelles 1
SI - Slovenia 1
SR - Suriname 1
TH - Thailandia 1
VI - Stati Uniti Isole Vergini 1
ZM - Zambia 1
Totale 11.211
Salva come PNG Salva come JPEG
Città #
Genoa 4.043
Genova 1.911
Vado Ligure 913
Rapallo 514
Ashburn 295
San Jose 271
Singapore 217
Council Bluffs 93
Beijing 88
Ho Chi Minh City 82
Lauterbourg 69
Milan 65
Hong Kong 63
Helsinki 60
New York 58
Hanoi 57
Boardman 37
Santa Clara 31
St Louis 31
Los Angeles 27
Frankfurt am Main 26
Bordighera 22
Tokyo 22
Rome 21
Naples 17
Da Nang 14
Bologna 13
Philadelphia 13
Haiphong 12
São Paulo 12
Valenza 12
Buffalo 11
Chicago 11
Atlanta 10
Dallas 9
Mexico City 9
Amsterdam 8
Phoenix 8
Tianjin 8
Turin 8
Can Tho 7
Orem 7
Des Moines 6
Dublin 6
Jacksonville 6
Kingston 6
London 6
Modena 6
Toronto 6
Vienna 6
Warsaw 6
Avon 5
Charlotte 5
City of London 5
Giessen 5
Goiânia 5
Istanbul 5
Montreal 5
Pittsburgh 5
San Antonio 5
Schiffdorf 5
Sydney 5
Zurich 5
Baghdad 4
Boston 4
Cleveland 4
Florence 4
Houston 4
Johannesburg 4
Kissimmee 4
New Delhi 4
Piscataway 4
Quận Ba 4
Suzhou 4
Tampa 4
Thái Nguyên 4
Verona 4
Berlin 3
Brugherio 3
Buenos Aires 3
Cairo 3
Chennai 3
Denver 3
Detroit 3
Fort Worth 3
Greenville 3
Hải Dương 3
Jakarta 3
Lappeenranta 3
Madrid 3
Nuremberg 3
Orlando 3
Ottawa 3
Quito 3
Quận Bình Thạnh 3
Richmond 3
Riverside 3
Rovereto 3
Rudolfstetten 3
Santo Domingo 3
Totale 9.444
Salva come PNG Salva come JPEG
Nome #
Guidelines for the diagnosis and treatment of basal cell carcinoma: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology 315
Heterogeneity and frequency of BRAF mutations in primary melanoma: Comparison between molecular methods and immunohistochemistry 260
Analisi fenotipica e funzionale dell’infiltrato linfocitario in biopsie di metastasi di melanoma, in pazienti in terapia con farmaci a bersaglio molecolare e/o inibitori dei checkpoint immunologici 238
BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. 236
Cytokines can counteract the inhibitory effect of MEK-i on NK-cell function 221
Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: Interplay between germline and somatic variations 219
CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients 214
Ataxia-Telangiectasia Mutated Loss of Heterozygosity in Melanoma 209
Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak 208
Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup 202
BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma 197
Clinical, pathological and dermoscopic phenotype of MITF p.E318K carrier cutaneous melanoma patients 189
Functional characterization of a multi-cancer risk locus on chr5p15.33 reveals regulation of TERT by ZNF148 187
Diagnosis of lung cancer following emergency admission: Examining care pathways, clinical outcomes, and advanced NSCLC treatment in an Italian cancer Center 171
HO-1 downregulation favors BRAFV600 melanoma cell death induced by Vemurafenib/PLX4032 and increases NK recognition 170
Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4+ tumor infiltrating lymphocytes and their in situ localization 166
Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma. 165
Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort 163
Phenotypic characterization of tumor CTLA-4 expression in melanoma tissues and its possible role in clinical response to Ipilimumab 162
CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab 161
Current State of Target Treatment in BRAF Mutated Melanoma 159
Insights into genetic susceptibility to melanoma by gene panel testing: Potential pathogenic variants in acd, atm, bap1, and pot1 158
Correction: Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: Interplay between germline and somatic variations [Oncotarget. 2018; 9:5691-5702]doi 10.18632/oncotarget.23204 157
Regenerative surgery for the definitive repair of a vasculitic nonhealing ulcer using platelet-derived growth factors and noncultured autologous cell suspension 150
Solar radiation as a risk factor for cutaneous melanoma: Review 149
Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis 148
Regenerative surgery for the definitive surgical repair of enterocutaneous fistula 146
Regenerative surgery for the definitive repair of chronic ulcers: a series of 34 cases treated with platelet-derived growth factors. 143
Front-line liquid biopsy for early molecular assessment and treatment of hospitalized lung cancer patients 142
Regenerative Medicine for the Treatment of Teno-desmic Injuries of the Equine. A Series of 150 Horses Treated with Platelet-derived Growth Factors 133
Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature 131
The Use of Platelet-rich Plasma Gel in Patients with Mixed Tumour Undergoing Superficial Parotidectomy: A Randomized Study 130
Development of a gene panel for hotspot mutation and copy number alterations based uveal melanoma prognostication. 129
Efficacy of braf and mek inhibition in patients with braf‐mutant advanced melanoma and germline cdkn2a pathogenic variants 127
Case Report: Immune-Related Toxicity During Adjuvant Treatment With BRAF Plus MEK Inhibitors in a Melanoma Patient 122
How to make immunotherapy an effective therapeutic choice for uveal melanoma 120
Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: A systematic review 119
Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications 117
Association of vacuum-assisted closure and platelet gel for the definitive surgical repair of an enterocutaneous fistula: a case report. 116
Whole-Exome Sequencing and cfDNA Analysis Uncover Genetic Determinants of Melanoma Therapy Response in a Real-World Setting 115
Primary endobronchial melanoma: a case report and clinical management indications 113
Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis 111
Immunotherapy in Adolescents and Young Adults: What Remains in Cancer Survivors? 109
Cerivastatin Synergizes with Trametinib and Enhances Its Efficacy in the Therapy of Uveal Melanoma 107
Association between PD-1 single nucleotide gene variants and the risk of metastatic melanoma 106
Assessing Determinants of Response to PARP Inhibition in Germline ATM Mutant Melanoma 104
Combined robotic inguinal and iliac-obturator lymphadenectomy for stage III skin cancers: Surgical technique and preliminary results 99
The treatment of melanoma brain metastases before the advent of targeted therapies: associations between therapeutic choice, clinical symptoms and outcome with survival 98
The treatment of advanced melanoma: Current approaches and new challenges 96
Influenza vaccination in cancer patients receiving immune checkpoint inhibitors: A systematic review 92
Interdependence of Molecular Lesions That Drive Uveal Melanoma Metastasis 90
The predictive and prognostic role of single nucleotide gene variants of PD-1 and PD-L1 in patients with advanced melanoma treated with PD-1 inhibitors 88
Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis 86
Hedgehog Inhibitors beyond Clinical Complete Response in Basal Cell Carcinoma: Should i Stop or Should i Go? 84
Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review 83
Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study 82
Early discontinuation of cemiplimab in patients with advanced cutaneous squamous cell carcinoma 82
Immunotherapy for resectable NSCLC: neoadjuvant/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses 82
The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape 81
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer 80
Molecular Assessment in Patients with Melanoma: When and Why? 77
Neoadjuvant treatments in patients with high-risk resectable stage III/IV melanoma 76
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study 76
Immunotherapy for the Treatment of Cutaneous Squamous Cell Carcinoma 74
Merkel Cell Carcinoma: An Immunotherapy Fairy-Tale? 74
Predictors of germline status for hereditary melanoma: 5 years of multi-gene panel testing within the Italian Melanoma Intergroup 72
Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy 70
Machine Learning Methods for Gene Selection in Uveal Melanoma 69
How I perform fertility preservation in breast cancer patients 69
mAbs targeting CTLA-4 and clinical outcomes 67
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice 67
Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial 67
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study 65
ADAM10 correlates with uveal melanoma metastasis and promotes in vitro invasion 64
Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology 61
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab 61
Safety of Extended interval Dosing Immune Checkpoint Inhibitors: a multicentre cohort study 60
Association of CTLA-4 gene variants with response to therapy and long-term survival in metastatic melanoma patients treated with ipilimumab: An Italian melanoma intergroup study 59
Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel 56
No impact of NRAS mutation on features of primary and metastatic melanoma or on outcomes of checkpoint inhibitor immunotherapy: An italian melanoma intergroup (IMI) study 53
Identification of prognostic liquid biopsy biomarkers in patients with cutaneous squamous cell carcinoma treated with cemiplimab 52
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index 52
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme 52
Current status and perspectives in immunotherapy for metastatic melanoma 51
Sun exposure and melanoma prognostic factors 51
Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma 51
Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma 51
The adjuvant treatment revolution for high-risk melanoma patients 50
Treatment of metastatic uveal melanoma with intravenous fotemustine 47
Update on Metastatic Uveal Melanoma: Progress and Challenges 46
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases 45
Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma 45
Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study 45
Uveal melanoma 45
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study 44
Immune-related osteitis mimicking femoral head osteonecrosis during dual checkpoint blockade: a case report 43
Characteristics of Real-World Patients with High-Risk BRAFV600E/K-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program 41
Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review 40
Binimetinib for the treatment of NRAS-mutant melanoma 39
Upcoming strategies for the treatment of metastatic melanoma 39
Totale 10.903
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.905
article - articoli 39.129
book - libri 0
conference - conferenze 327
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 858
Totale 81.219
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022449 26 21 23 46 21 43 19 84 40 63 13 50
2022/2023624 51 52 6 53 112 94 4 48 90 8 98 8
2023/2024607 12 42 18 82 34 82 21 56 31 30 36 163
2024/20252.637 107 171 54 143 302 253 198 381 104 110 265 549
2025/20265.242 511 217 678 483 529 303 641 262 436 502 352 328
2026/2027376 376 0 0 0 0 0 0 0 0 0 0 0
Totale 11.506